Skip Navigation

Cardiovascular Research 2001 49(3):561-567; doi:10.1016/S0008-6363(00)00257-1
© 2001 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Hammond, H.K.
Right arrow Articles by McKirnan, M.D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hammond, H.K.
Right arrow Articles by McKirnan, M.D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2001, European Society of Cardiology

Angiogenic gene therapy for heart disease: a review of animal studies and clinical trials

H.Kirk Hammonda,* and M.Dan McKirnanb

aSan Diego VA Healthcare System, Department of Medicine, University of California (111A) 3350 La Jolla Village Drive, San Diego, CA 92161, USA
bCollateral Therapeutics, San Diego, CA, USA

* Corresponding author. Tel.: +1-858-552-8585, ext. 3542; fax: +1-858-642-6213 khammond{at}ucsd.edu

The current published clinical literature on angiogenic gene therapy for the treatment of myocardial ischemia does not include a single randomized, placebo-controlled trial. Based on current clinical literature, it is an unproven therapy. Successful animal studies combined with published reports of good outcomes in patients enrolled in uncontrolled trials has led to the expectation that angiogenic gene therapy will ultimately become a clinical reality. The next important landmark in the field will be the publication of data showing a favorable effect of angiogenic gene transfer in placebo-controlled, blinded clinical trials.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
D. Zisa, A. Shabbir, M. Mastri, G. Suzuki, and T. Lee
Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cells
Am J Physiol Regulatory Integrative Comp Physiol, November 1, 2009; 297(5): R1503 - R1515.
[Abstract] [Full Text] [PDF]

Home page
 J. Thorac. Cardiovasc. Surg.Home page
D. Chu, C. C. Sullivan, M. D. Weitzman, L. Du, P. L. Wolf, S. W. Jamieson, and P. A. Thistlethwaite
Direct comparison of efficiency and stability of gene transfer into the mammalian heart using adeno-associated virus versus adenovirus vectors
J. Thorac. Cardiovasc. Surg., September 1, 2003; 126(3): 671 - 679.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. Roguin, A. Avivi, S. Nitecki, I. Rubinstein, N. S. Levy, Z. A. Abassi, M. B. Resnick, O. Lache, M. Melamed-Frank, A. Joel, et al.
Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF
PNAS, April 15, 2003; 100(8): 4644 - 4648.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
R. Khurana, J. F. Martin, and I. Zachary
Gene Therapy for Cardiovascular Disease: A Case for Cautious Optimism
Hypertension, November 1, 2001; 38(5): 1210 - 1216.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.